Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies

• Main Authors: Yizhou Zhang (Author), Ruicheng Wei (Author), Ge Song (Author), Xinyi Yang (Author), Mengli Zhang (Author), Wei Liu (Author), Aiying Xiong (Author), Xuehan Zhang (Author), Qianhao Li (Author), Wan-Jen Yang (Author), Chencheng Han (Author), Rui Liu (Author), Chen Hu (Author), Qingyu Wang (Author), Jun Zhu (Author), Yongqiang Shan (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

With more than 20 anti-PD-1/PD-L1 antibodies currently marketed, anti-PD-1 therapy has become a cornerstone of tumor immunotherapy. These agents, however, exhibit notable disparities in their characteristics and clinical performance. For instance, in the field of small cell lung cancer (SCLC) where...